What is Synjardy used for?
Synjardy is a prescription medicine for type 2 diabetes. It combines two active ingredients: empagliflozin and metformin. It’s used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes. [1]
How does Synjardy work (empagliflozin + metformin)?
Synjardy pairs two mechanisms in one product. Metformin helps reduce glucose production in the liver and improves insulin sensitivity. Empagliflozin is an SGLT2 inhibitor that helps the kidneys remove excess glucose from the bloodstream through urine. [1]
What doses are available?
Synjardy is sold in different strengths that pair empagliflozin with metformin, with formulations commonly described as 5 mg/500 mg, 5 mg/850 mg, 12.5 mg/500 mg, and 12.5 mg/850 mg (empagliflozin/metformin), depending on the specific product strength. [1]
Who might not be able to take Synjardy?
As with other products containing metformin and an SGLT2 inhibitor, clinicians typically consider kidney function, since both components can be affected by renal status. Synjardy is also generally not used for type 1 diabetes or diabetic ketoacidosis. [1]
What side effects do people ask about?
Common questions and side effects associated with this drug class include gastrointestinal effects related to metformin and genital yeast infections or urinary tract infections related to SGLT2 inhibitors. Patients also ask about dehydration-related symptoms (such as dizziness) and signs of rare but serious complications. [1]
Is Synjardy protected by patents, and when does exclusivity end?
DrugPatentWatch.com tracks patent and exclusivity information for specific branded products. If you share the exact Synjardy brand spelling you mean (for example, Synjardy vs. Synjardy XR), I can point to the most relevant listing and current status there. [2]
---
Sources
[1] https://www.drugs.com/synjardy.html
[2] https://www.drugpatentwatch.com/